HOME > REGULATORY
REGULATORY
- MHLW Plans to Set Up Medical Information Database at 6 Base Locations in FY2012
February 22, 2012
- MHLW to Improve Review System Based on Regulatory Science: PFSB Director General Yoshiyuki Kikura
February 22, 2012
- MHLW Warns Manufacturers to Take Steps to Ensure Proper Use of Anti-Influenza Drugs
February 22, 2012
- MHLW Issues Notification to Publicize FPMAJ’s Crude and Kampo Drug Standards
February 20, 2012
- MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
- Domestic Pharmaceutical Production Down 0.6% in 2010; First Decline in Six Years
February 20, 2012
- 105 Nu-lotan Generics from 35 Companies Approved for June Listing, 60% Pricing to Apply
February 16, 2012
- Medical Innovation Council Executive Meeting to Set Next 5-Year Plan by May
February 16, 2012
- MHLW to Revise Notification on GMP Inspection Requirements to Prepare for Participation in PIC/S
February 16, 2012
- PAFSC’s 2nd Committee on New Drugs to Discuss Approval for Pfizer Japan’s ALK Inhibitor Xalkori
February 16, 2012
- Osaka Prefecture Asking Korosho to Provide Pharmaceutical Strategy Consultation Services in Kansai Region
February 16, 2012
- Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
- Prof. Matsumoto of OPMI Stresses Need to Enhance Competitiveness of Pharmaceutical Industry
February 14, 2012
- MHLW Postpones Ban of Dispensing Points to October
February 14, 2012
- PAFSC’s First Committee on Drugs to Review Astellas’ Hyperphosphatemia Treatment on February 24
February 14, 2012
- Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
- CSIMC’S Medical Fee Reform Plan for FY2012 to Promote Faster Patient Discharge, Functional Specialization
February 13, 2012
- FY2012 Medical Fee Revision to Include New Measures to Promote Generic Drug Use
February 13, 2012
- Guidance Fee for Psychiatric Patients to Be Reduced from 55 to 44 Points When Prescribing 3 or More Drugs
February 10, 2012
- Delivery Price Settlement Rate Just 79.1% at End of December: MHLW
February 9, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…